G42

UAE-registered boat BAYANAT embarks on world's longest and most grueling sailing race

Retrieved on: 
Thursday, September 8, 2022
Abhilash Tomy, CEO, Technology, Circumnavigation, Korea Cup, Pain, Sunday Times Golden Globe Race, Achievement, Navy, ABU, 2018 Golden Globe Race, Courage, G42, CDR, Indian Navy, News, Golden Globe Awards, GGR, Microplastics, Cape Town, Online gambling, Shipbuilding, Entertainment

The Golden Globe Race (GGR) is a non-stop solo circumnavigation of the world by sea using technology available no later than 1968.

Key Points: 
  • The Golden Globe Race (GGR) is a non-stop solo circumnavigation of the world by sea using technology available no later than 1968.
  • Abhilash's ambition to compete again was realized by Bayanat, a G42 company that is pioneering responsible geospatial AI and transforming industries.
  • Bayanat, a G42 company based in Abu Dhabi that provides AI-powered geospatial intelligence solutions, is sponsoring Abhilash's participation in the race.
  • The boat, aptly named 'BAYANAT' bears the race number 71, a tribute to 1971, the year in which the UAE came into being.

UAE-registered boat BAYANAT embarks on world's longest and most grueling sailing race

Retrieved on: 
Thursday, September 8, 2022
Abhilash Tomy, CEO, Technology, Circumnavigation, Korea Cup, Pain, Sunday Times Golden Globe Race, Achievement, Navy, ABU, 2018 Golden Globe Race, Courage, G42, CDR, Indian Navy, News, Golden Globe Awards, GGR, Microplastics, Cape Town, Online gambling, Shipbuilding, Entertainment

The Golden Globe Race (GGR) is a non-stop solo circumnavigation of the world by sea using technology available no later than 1968.

Key Points: 
  • The Golden Globe Race (GGR) is a non-stop solo circumnavigation of the world by sea using technology available no later than 1968.
  • Abhilash's ambition to compete again was realized by Bayanat, a G42 company that is pioneering responsible geospatial AI and transforming industries.
  • Bayanat, a G42 company based in Abu Dhabi that provides AI-powered geospatial intelligence solutions, is sponsoring Abhilash's participation in the race.
  • The boat, aptly named 'BAYANAT' bears the race number 71, a tribute to 1971, the year in which the UAE came into being.

CyberArrow and G42 Cloud Announce New Partnership

Retrieved on: 
Thursday, September 1, 2022
Cloud, Partnership, Risk management, CEO, Posture, Government, Solution, Cloud computing, G42, Organization, Governance, risk management, and compliance, GLOBE, Compliance, Memorandum of understanding, GRC, Ecosystem, Automation, AI

G42 Cloud is a subsidiary of leading AI and cloud computing provider G42, and its powerful cloud and market presence have helped CyberArrow to continue to scale its operation and reach more customers across MENA by becoming one of the ecosystem partners that can be hosted and deployed to customers on G42 Cloud.

Key Points: 
  • G42 Cloud is a subsidiary of leading AI and cloud computing provider G42, and its powerful cloud and market presence have helped CyberArrow to continue to scale its operation and reach more customers across MENA by becoming one of the ecosystem partners that can be hosted and deployed to customers on G42 Cloud.
  • CyberArrow works with organizations of all sizes, supporting them to enhance their cyber security resilience and posture.
  • Amar Basic, Co-Founder of CyberArrow, said, "We are excited to be working with G42 Cloud.
  • Talal Al Kaissi, CEO of G42 Cloud added, "We are looking forward to working with CyberArrow in order to enhance our ecosystem offerings with one of the top cyber security solutions which can now be served on our sovereign cloud to the government sector.

vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 15, 2022
FDA, Regulation of tobacco by the U.S. Food and Drug Administration, T1D, Risk, Type 2 diabetes, Industry, DKA, GLOBE, CEO, Food, R, Clinical trial, Sale, VTV, Board, Diabetic ketoacidosis, General Administration of Press and Publication, Income, Marketing, Quality of life, Patient, Ketoacidosis, Therapy, American Diabetes Association, Company, Hypoglycemia, Research and development, Program, G&A, Receptor (biochemistry), Diabetes, Obesity and Metabolism, Expense, Nasdaq, Metabolism, Administration, Management, Pharmaceutical industry, G42

HIGH POINT, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the second quarter ended June30, 2022, and provided an update on recent corporate developments.

Key Points: 
  • HIGH POINT, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the second quarter ended June30, 2022, and provided an update on recent corporate developments.
  • On July 27, 2022, the Company appointed Paul Sekhri as President, Chief Executive Officer (CEO) effective August 1, 2022, and was confirmed as a member of the board of directors on August 9, 2022.
  • Net Loss:Net loss attributable to vTv shareholders for the three months ended June30, 2022, was $3.2 million or $0.04 per basic share.
  • Net loss attributable to vTv shareholders for the comparable period a year ago was $0.6 million or $0.01 per basic share.

vTv Therapeutics Announces Investment by CinRx Pharma

Retrieved on: 
Monday, July 25, 2022
Sale, Common, Partnership, Breakthrough therapy, Review, Interim, Insulin, Doctor of Philosophy, Harvard Medical School, LLC, G42, Investment, Diabetes, Common stock, Sumathi Best Television Current Reporting Award, Biotechnology, Food, Faculty, Pharmacology, GLOBE, Industry, Medicine, Internal medicine, SEC, Pancreatic cancer, Disease, FDA, Cardiology, Nasdaq, Therapy, Annual report, Metabolism, Kidney, Chronic obstructive pulmonary disease, Risk, Ketoacidosis, Teva Pharmaceuticals, VTV, Drug development, Yale School of Medicine, Patient, Terminology, Cystic fibrosis, Pharmaceutical industry, Medpace

HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (CinPax), a subsidiary of CinRx Pharma, LLC (CinRx).

Key Points: 
  • HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (CinPax), a subsidiary of CinRx Pharma, LLC (CinRx).
  • In addition to the $10 million investment, the CinRx team brings exceptional industry experience in developing therapeutics.
  • On top of last months announcement of G42 Healthcares $25 million investment into vTv, this investment provides additional funding towards our Phase 3 clinical trials for TTP399, said Rich Nelson, Interim Chief Executive Officer of vTv.
  • Dr. Jon Isaacsohn, Chief Executive Officer of CinRx, who has been involved in the clinical development of countless therapeutics, is expected to join the vTv Board of Directors.

G42 Healthcare and AstraZeneca Sign Agreement to Advance Life Sciences at BIO International Convention

Retrieved on: 
Tuesday, June 21, 2022
Solution, Oncology, Department of Health (Abu Dhabi), Department, AstraZeneca, Vaccines Manufacturing and Innovation Centre, Intelligence, United Arab Emirates, Health care, View, CEO, Research, Corporate Affairs, Letter, LOI, Doh, Emirate, Associate, Partnership, Patient, Cloud computing, Multimedia, Organization, Medical tourism, RWE, Pharmaceutical industry, G42

Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.

Key Points: 
  • Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.
  • G42 Healthcare and AstraZeneca initially signed a Declaration of Collaboration in December 2021.
  • Ashish Koshy, CEO of G42 Healthcare, said, "We value collaboration and believe the strategic partnership with AstraZeneca will yield incredible growth for the healthcare ecosystem.
  • Hicham Mirghani, Corporate Affairs Director GCC, AstraZeneca said, "We are excited about expanding our existing partnership with G42 Healthcare to further advance the healthcare sector in the country and region.

G42 Healthcare and AstraZeneca Sign Agreement to Advance Life Sciences at BIO International Convention

Retrieved on: 
Tuesday, June 21, 2022
Solution, Oncology, Department of Health (Abu Dhabi), Department, AstraZeneca, Vaccines Manufacturing and Innovation Centre, Intelligence, United Arab Emirates, Health care, CEO, Research, Corporate Affairs, Letter, LOI, Doh, Emirate, Associate, Partnership, Patient, Cloud computing, Organization, Medical tourism, RWE, Pharmaceutical industry, G42

Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.

Key Points: 
  • Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.
  • G42 Healthcare and AstraZeneca initially signed a Declaration of Collaboration in December 2021.
  • Ashish Koshy, CEO of G42 Healthcare, said, "We value collaboration and believe the strategic partnership with AstraZeneca will yield incredible growth for the healthcare ecosystem.
  • Hicham Mirghani, Corporate Affairs Director GCC, AstraZeneca said, "We are excited about expanding our existing partnership with G42 Healthcare to further advance the healthcare sector in the country and region.

G42 Healthcare and AstraZeneca Sign Agreement to Advance Life Sciences at BIO International Convention

Retrieved on: 
Tuesday, June 21, 2022
Solution, Oncology, Department of Health (Abu Dhabi), Department, AstraZeneca, Vaccines Manufacturing and Innovation Centre, Intelligence, United Arab Emirates, Health care, CEO, Research, Corporate Affairs, Letter, LOI, Doh, Emirate, Associate, Partnership, Patient, Cloud computing, Organization, Medical tourism, RWE, Pharmaceutical industry, G42

Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.

Key Points: 
  • Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.
  • G42 Healthcare and AstraZeneca initially signed a Declaration of Collaboration in December 2021.
  • Ashish Koshy, CEO of G42 Healthcare, said, "We value collaboration and believe the strategic partnership with AstraZeneca will yield incredible growth for the healthcare ecosystem.
  • Hicham Mirghani, Corporate Affairs Director GCC, AstraZeneca said, "We are excited about expanding our existing partnership with G42 Healthcare to further advance the healthcare sector in the country and region.

G42 Healthcare and AstraZeneca Sign Agreement to Advance Life Sciences at BIO International Convention

Retrieved on: 
Tuesday, June 21, 2022
Solution, Oncology, Department of Health (Abu Dhabi), Department, AstraZeneca, Vaccines Manufacturing and Innovation Centre, Intelligence, United Arab Emirates, Health care, CEO, Research, Corporate Affairs, Letter, LOI, Doh, Emirate, Associate, Partnership, Patient, Cloud computing, Organization, Medical tourism, RWE, Pharmaceutical industry, G42

Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.

Key Points: 
  • Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.
  • G42 Healthcare and AstraZeneca initially signed a Declaration of Collaboration in December 2021.
  • Ashish Koshy, CEO of G42 Healthcare, said, "We value collaboration and believe the strategic partnership with AstraZeneca will yield incredible growth for the healthcare ecosystem.
  • Hicham Mirghani, Corporate Affairs Director GCC, AstraZeneca said, "We are excited about expanding our existing partnership with G42 Healthcare to further advance the healthcare sector in the country and region.

vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare

Retrieved on: 
Wednesday, June 1, 2022
Ketoacidosis, Science, Cystic fibrosis, Leadership, Breakthrough therapy, Collaboration, Program, Marketing, Knowledge, Common stock, Annual report, Sumathi Best Television Current Reporting Award, Investment, COVID-19 testing, Pancreatic cancer, Nasdaq, Kidney, Chronic obstructive pulmonary disease, Sale, FDA, Therapy, Patient, Insulin, GLOBE, Risk, VTV, Diabetes, Health, Review, COVID-19, Union, SEC, Food, Genomics, Interim, Terminology, Pharmaceutical industry, G42

HIGH POINT, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd (G42 Investments).

Key Points: 
  • HIGH POINT, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd (G42 Investments).
  • The Stock Purchase Agreement is attached to the Current Report on Form 8-K and the Collaboration and License Agreement will be filed with vTv's Quarterly Report on Form 10-Q for the second quarter.
  • G42 Healthcare, headquartered in the UAE, is a health-tech company on a mission to develop a world-class healthcare sector in the UAE and beyond.
  • At the forefront in the battle against COVID-19, G42 Healthcare established Biogenix Labs, the UAEs first COVID-19 accredited large-scale throughput laboratory.